Month: August 2020

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) — Spartan Energy Acquisition Corp. (“Spartan”) (NYSE:SPAQ), a special purpose acquisition company (“SPAC”) sponsored by an affiliate of Apollo Global Management, Inc. (NYSE:APO), today announced that its stockholders approved an extension of the date by which it has to complete a business combination from August 14, 2020 to February 14, 2021. Spartan requested the extension in order to complete the previously announced proposed business combination (the “Fisker Transaction”) with Fisker Inc. (“Fisker”).The Fisker Transaction is expected to be completed in the fourth quarter of 2020, subject to, among other things, the approval by Spartan’s stockholders, satisfaction of the conditions stated in the definitive agreement and other customary closing conditions.About Spartan Energy Acquisition Corp.Spartan...

Orlando, Florida, Aug. 06, 2020 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), the premier provider of influencer marketing technology, data, and services for the world’s leading brands, announced today that it will be launching an influencer marketing campaign in partnership with Doe-Anderson, headquartered in Louisville, Ky. to drive awareness and education about the benefits of wearing a mask to reduce the spread of COVID-19 for the Commonwealth of Kentucky.“We are proud to partner with the Commonwealth of Kentucky to help combat misconceptions about masks and assist in reducing the spread of COVID-19,” said Ted Murphy, Founder and CEO of IZEA. “The proper use of masks has been shown to have a material impact on reducing the spread of the virus, and our company is in complete support of the state’s efforts to better...

Westport, CT, Aug. 06, 2020 (GLOBE NEWSWIRE) —Expert in Infectious Diseases and Immune OncologyViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against COVID-19BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced the addition of Professor Angus Dalgleish to its Scientific Advisory Board (SAB).Angus Dalgleish, M.D. is the Foundation Chair of Oncology and Honorary Consultant in Medical Oncology at St. George’s University and Hospital in London and Principal of the Institute of Cancer Vaccines and Immunotherapy. He is a fellow of the Royal College of Physicians both in the UK and Australia, the Royal College of Pathologists, and the Academy of Medical Sciences (UK). Prof. Dalgleish published seminal papers...

MCLEAN, Va., Aug. 06, 2020 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing that the 30-year fixed-rate mortgage (FRM) averaged 2.88 percent, the lowest rate in the survey’s history dating back to 1971.“The resilience of the housing market continues as mortgage rates hit another all-time low, giving potential buyers more purchasing power and strengthening demand,” said Sam Khater, Freddie Mac’s Chief Economist. “We expect rates to stay low and continue to propel the purchase market forward. However, the main barrier to rising demand remains the lack of inventory, especially for entry-level homes.”News Facts30-year fixed-rate mortgage averaged 2.88 percent with an average 0.8 point for the week ending August 6, 2020, down from last week when it averaged...

VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) — Liquid Media Group Ltd. (the “Company”, “Liquid Media” or “Liquid”) (Nasdaq: YVR) is pleased to announce it has retained Novus Merchant Partners Inc. (“Novus”) as its capital markets advisor.  Novus will assist the Company in developing, implementing and executing on its business strategy of consolidating and vertically integrating intellectual property (IP) rights with production capabilities to leverage innovative technology as well as owned IP into full media franchises.  As part of its mandate, Novus will act as financial advisor to the Company on strategic M&A transactions.Novus is a merchant and investment banking firm co-founded by Charles Shin and Ron Rimer, who together have led or co-led over USD$10.5-billion in financing and M&A transactions. Novus’s...

Las Vegas, NV, Aug. 06, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Hemp, Inc. (OTC PINK: HEMP) announced today that sales to date, from their premium hemp flower, Pre-98 OG Bubba Kush, have surpassed their $2,000,000 groundbreaking milestone.  The Company has reached $2,098,117.04 (up $1,062,300 from sales reported, after surpassing its first milestone of $1,000,000, in a past press release on 5/26/20). That’s a total increase of $1,062,300 over the past ten weeks.  The Company expects to hit groundbreaking milestones quarterly, with other products to come.Hemp, Inc.’s CEO, Bruce Perlowin, admits it was very frustrating and full of delays during the first quarter due to the COVID-19 pandemic but says the Company has been “full speed ahead” since then.  “We’ve also started our mass marketing campaigns so I’m certain we will...

Nasdaq Copenhagen A/S                                                      Meddelelse nr.                           6/2020Nicolai Plads 6                                                     Fondskode.                DK 00102835971007 København K                                                CVR nr.                                 15313714                                                                             LEI kode:      990  0NJCIEGWTL0U036                                       Kontaktperson                                                                               Peter Hansen           Tlf. 36931011        Delårsrapport for perioden 1. januar – 30. juni 2020 og forventning til resultatet for 2020Andersen & Martini realiserer et underskud på godt t.kr. 300 før skat i første halvår 2020 og forventer et resultat...

Nasdaq Copenhagen A/S                                                      Meddelelse nr.                           6/2020Nicolai Plads 6                                                     Fondskode.                DK 00102835971007 København K                                                CVR nr.                                 15313714                                                                             LEI kode:      990  0NJCIEGWTL0U036                                       Kontaktperson                                                                               Peter Hansen           Tlf. 36931011        Delårsrapport for perioden 1. januar – 30. juni 2020 og forventning til resultatet for 2020Andersen & Martini realiserer et underskud på godt t.kr. 300 før skat i første halvår 2020 og forventer et resultat...

Amarin va créer une organisation dédiée pour conserver une valeur substantielle de l’un des médicaments cardiovasculaires les plus attendus depuis des décenniesUn dirigeant commercial chevronné spécialisé dans les maladies cardiovasculaires a été engagé pour mener le lancement cibléDUBLIN, Irlande et BRIDGEWATER, New Jersey, 06 août 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ : AMRN) a annoncé aujourd’hui les projets de la société pour entreprendre son propre lancement commercial ciblé de VASCEPA® ( icosapent éthyl) en Europe.  Le projet d’Amarin est soumis à l’examen et à l’approbation de sa demande d’autorisation de mise sur le marché (AMM) par l’Agence européenne des médicaments et la Commission européenne, respectivement. Le demande est en phase d’examen avancée pour...

Amarin baut engagierte Organisation auf, um den erheblichen Wert eines der am meisten erwarteten kardiovaskulären Arzneimittel seit Jahrzehnten zu erhaltenErfahrene Führungskraft im Bereich der Vermarktung von kardiovaskulären Arzneimittel wurde eingestellt, um die fokussierte Markteinführung zu leitenDUBLIN, Irland und BRIDGEWATER, New Jersey, Aug. 06, 2020 (GLOBE NEWSWIRE) — Die Amarin Corporation plc (NASDAQ: AMRN) hat heute die Pläne des Unternehmens bekanntgegeben, die fokussierte Markteinführung von VASCEPA® (Icosapent-Ethyl) in Europa selbst voranzutreiben. Der Plan von Amarin unterliegt der Überprüfung und Genehmigung seines Zulassungsantrags (MAA) durch die Europäische Arzneimittel-Agentur bzw. die Europäische Kommission. Der Antrag befindet sich in einem späten Stadium der Überprüfung in Bezug auf die Reduzierung des kardiovaskulären...